^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SynKIR-110

    i
    Other names: SynKIR-110, autologous T cells transduced with mesothelin KIR-CAR, SynKIR110, SynKIR 110
    Company:
    HLB Bio Group, University of Pennsylvania, Verismo Therap
    Drug class:
    Mesothelin-targeted CAR-T immunotherapy
    Related drugs:
    10d
    Trio of Phase I Studies Investigates Mesothelin-Directed CAR T-Cell Therapies. (PubMed, Cancer Discov)
    At the American Association for Cancer Research Annual Meeting, researchers presented data from three separate phase I studies investigating distinct mesothelin-targeted chimeric antigen receptor T-cell therapies: SynKIR-110, UCMYM802, and M28z1XXPD1DNR.
    P1 data • Journal
    |
    MSLN (Mesothelin)
    |
    SynKIR-110
    1year
    A Long-Term Follow-Up Basket Study for Participants Treated with SynKIR Chimeric Antigen Receptor (CAR) T Cell Product (clinicaltrials.gov)
    P=N/A, N=60, Enrolling by invitation, Verismo Therapeutics | Not yet recruiting --> Enrolling by invitation
    Enrollment open
    |
    SynKIR-110
    over1year
    A Long-Term Follow-Up Basket Study for Participants Treated with SynKIR Chimeric Antigen Receptor (CAR) T Cell Product (clinicaltrials.gov)
    P=N/A, N=60, Not yet recruiting, Verismo Therapeutics
    New trial • Pan tumor
    |
    SynKIR-110
    over1year
    Long-Term Follow-Up Safety Study of Subjects Treated with SynKIR-110 in Cancer Studies (clinicaltrials.gov)
    P=N/A, N=0, Withdrawn, Verismo Therapeutics | N=100 --> 0 | Recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    SynKIR-110
    over1year
    SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma (clinicaltrials.gov)
    P1, N=42, Recruiting, Verismo Therapeutics | Trial completion date: Mar 2026 --> Dec 2027 | Trial primary completion date: Mar 2026 --> Dec 2027
    Trial completion date • Trial primary completion date • Metastases
    |
    MSLN (Mesothelin)
    |
    SynKIR-110
    2years
    Long-Term Follow-Up Safety Study of Subjects Treated With SynKIR-110 in Cancer Studies (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Verismo Therapeutics
    New trial
    |
    SynKIR-110
    over2years
    Preclinical potency assessment of SynKIR-110, a mesothelin-specific KIR-CAR T cell therapy for mesothelioma (SITC 2023)
    These data support further clinical development of SynKIR-110 in patients with advanced solid tumors. SynKIR-110 is currently being investigated in a Phase I clinical trial STAR-101 (NCT05568680).
    Preclinical • CAR T-Cell Therapy
    |
    MSLN (Mesothelin)
    |
    MSLN positive
    |
    SynKIR-110
    3years
    SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma (clinicaltrials.gov)
    P1, N=42, Recruiting, Verismo Therapeutics | Not yet recruiting --> Recruiting | Initiation date: Dec 2022 --> Mar 2023
    Enrollment open • Trial initiation date • Metastases
    |
    MSLN (Mesothelin)
    |
    MSLN expression
    |
    SynKIR-110
    over3years
    SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma (clinicaltrials.gov)
    P1, N=42, Not yet recruiting, Verismo Therapeutics
    New P1 trial • Metastases
    |
    MSLN (Mesothelin)
    |
    MSLN expression
    |
    SynKIR-110